Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing on new clinical targets. Votucalis captures histamine and thereby has the unique potential to prevent activation of all four histamine
NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration ( FDA) and European Medicines Agency (EMA) meetings earlier in the year. Phase III study in severe pediatric hematopoietic
New data accrued from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence. Transfusion independence of 79% reported for 14 formerly transfusion dependent PNH patients treated with
New data highlight role of leukotriene B4 (LTB4) in the pathophysiology of retinal inflammation and degeneration I n the experimental allergic uveitis (EAU) disease model nomacopan reduce d Th17 effector T cell and macrophage activity in addition to known downregulation of neutrophils Long-acting
Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BP The Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to a Phase III randomised placebo - controlled study usin g nomacopan for treatment of BP Phase III
FDA clearance received to proceed with investigator- led multi-center double blind randomized clinical study in the U . S . with nomacopan following prior expanded access program Following initial proof of principle study in Brazil and subsequent Data and Safety Monitoring Board (DSMB) review, a
The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of disease remission on minimal oral corticosteroids (OCS) Nomacopan has been granted orphan drug designation by the
NEW YORK and LONDON , Sept. 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,
NEW YORK and LONDON , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,